ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
33.83
+0.17 (0.51%)
After Hours: 33.57 -0.26 (-0.77%)
Apr 27, 4:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.08 - 33.92
52 week 20.68 - 42.49
Open 33.68
Vol / Avg. 1.04M/1.25M
Mkt cap 3.98B
P/E     -
Div/yield     -
EPS -2.33
Shares 121.41M
Beta 3.92
Inst. own 102%
Jun 9, 2017
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 3, 2017
Q1 2017 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 5, 2017
ACADIA Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 6, 2017
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 28, 2017
Q4 2016 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Feb 28, 2017
Q4 2016 ACADIA Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -657.88% -1565.94%
Operating margin -654.00% -1574.14%
EBITD margin - -1563.60%
Return on average assets -53.57% -69.32%
Return on average equity -57.58% -75.58%
Employees 370 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Officers and directors

Stephen R. Biggar M.D. Ph.D. Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Todd S Young Chief Financial Officer, Executive Vice President, Principal Financial Officer and Principal Accounting Officer
Age: 44
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 59
Bio & Compensation  - Reuters
Michael J. Yang Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 50
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 63
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 58
Bio & Compensation  - Reuters